This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

CVS Deal Could Be Nice 'Tuck-In': Analyst

NEW YORK ( TheStreet) -- CVS Caremark's (CVS - Get Report) $1.25 billion acquisition of Universal American's Medicare's (UAM) Medicare Part D business could be a nice "tuck-in" for the company as long as CVS does not repeat its history with integrations in the pharmacy benefit management (PBM) space, says Jeff Jonas, an analyst at Gabelli & Co.

The biggest issue confronting the deal's success is likely to be the integration, with which CVS has had a rocky past. Its last PBM integration was the Caremark deal.

"That was an issue for them. The biggest issue was in the marketing message: convenience, and customers wanted low prices. They didn't quite have the right messege," explains Jonas. "CVS wound up losing a bunch of customers they served in the Medicare Part D business because when they submitted their bids, they were higher than competitors."

Jonas says that with new management, the integration could go better. He points out that CVS could also use the synergies between the comapnies to reinvest in comparative rates.

"The deal should give them a small addition to earnings that will be accretive immediately," said Jonas. "CVS could get 5 to 10 cents per share on earnings by 2012, when the deal is fully integrated. "

The price of eight times EBITDA was "fair" for the shareholders of both comapnies, Jonas said. Similar PBM deals that included sales books and claims processing such as the Express Scripts (ESRX - Get Report) deal with WellPoint's (WLP) NextRx for $4.6 billion in 2009 went for 12 times EBITDA because they included more products.

In 2011, CVS Caremark is likely to continue to make even smaller tuck-in deals.

"They are focused on increasing dividend and then buying back stock," Jonas said. "If they do anything to strengthen on the PBM side they have this partnership with Generation Health with genetic testing or they could strengthen in their specialty-drug business. They could also make acquisitions on their retail side. They have a hole in the Pacific Northwest they could fill in there."

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
WLP $136.01 1.43%
CVS $95.86 0.00%
ESRX $67.34 0.00%
UAM $6.06 0.00%
AAPL $93.99 0.00%


Chart of I:DJI
DOW 15,973.84 +313.66 2.00%
S&P 500 1,864.78 +35.70 1.95%
NASDAQ 4,337.5120 +70.6750 1.66%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs